Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 9NIH 7INDUSTRY 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Breast 73Tumor-Agnostic 6Gastrointestinal 6CNS 5Head & Neck 3Genitourinary 3Thoracic 2Gynecologic 2Other solid neoplasm 1

Conditions

Breast Neoplasms 4Brain Neoplasms 4Neoplasms 2Recurrence 1Glioma 1Glioblastoma 1

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Lapatinib × CNS × Clear all
NCT00263588 2019-12-12

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Novartis

Phase 2 Completed
242 enrolled 19 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms

NCT00820222 2019-04-02

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Novartis

Phase 3 Completed
540 enrolled 18 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00437073 2015-10-15

Brain Metastases In ErbB2-Positive Breast Cancer

GlaxoSmithKline

Phase 2 Terminated
22 enrolled 8 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01077648 2014-05-26

Brain Metastasis in Breast Cancer Patients

GlaxoSmithKline

Completed
1 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms

NCT00350727 2013-04-19

VEG102857

GlaxoSmithKline

Phase 2 Completed
75 enrolled 45 charts
CNS

Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡